Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004

#	Paper	IF	Citations
237	Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004. *Breast Cancer Research and Treatment*, **2010**, 120, 217-27	4.4	14
236	Health disparities in breast cancer: biology meets socioeconomic status. *Breast Cancer Research and Treatment*, **2010**, 121, 281-92	4.4	76
235	Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival. *Breast Cancer Research and Treatment*, **2010**, 123, 177-87	4.4	40
234	Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. **2010**, 37, 384-401		31
233	Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. **2010**, 10, 228		59
232	The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. **2010**, 8, 27		32
231	The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey. **2010**, 116, 5348-57		15
230	Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. **2010**, 16, 6100-10		286
229	Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. **2010**, 12, R99		117
228	Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study. **2011**, 37, 876-82		42
227	Is the Oncotype DX Assay Necessary in Strongly Estrogen Receptor-Positive Breast Cancers?. **2011**, 77, 1364-1367		9
226	Epidemiology of triple negative breast cancers. **2010**, 32, 5-24		39
225	Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. **2011**, 11, 292		80
224	Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type. **2011**, 19, 640-51		119
223	Potential impact of USPSTF recommendations on early diagnosis of breast cancer. **2011**, 18, 3137-42		11
222	Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. *Breast Cancer Research and Treatment*, **2011**, 126, 671-8	4.4	36
221	Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. *Breast Cancer Research and Treatment*, **2011**, 127, 471-8	4.4	118

220	Triple negative breast cancer: unmet medical needs. *Breast Cancer Research and Treatment*, **2011**, 125, 627-36	4.4	226
219	Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. *Breast Cancer Research and Treatment*, **2011**, 127, 297-308	4.4	37
218	Differential expression of prognostic biomarkers between interval and screen-detected breast cancers: does age or family history matter?. *Breast Cancer Research and Treatment*, **2011**, 129, 211-9	4.4	8
217	Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. **2011**, 22, 775-83		57
216	Breast cancer subtypes and survival in chinese women with operable primary breast cancer. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2011**, 23, 134-9	3.8	12
215	A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. **2011**, 11, 149		59
214	Higher population-based incidence rates of triple-negative breast cancer among young African-American women : Implications for breast cancer screening recommendations. **2011**, 117, 2747-53		140
213	The enduring and evolving relationship between social class and breast cancer burden: a review of the literature. **2011**, 35, 217-34		42
212	Ethnic disparities in breast tumor phenotypic subtypes in Hispanic and non-Hispanic white women. **2011**, 20, 1543-50		35
211	Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG. **2011**, 197, W247-55		48
210	[Breast cancer in Sub-Saharan African women: review]. **2011**, 98, 797-806		33
209	Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. **2012**, 23, 3007-3016		63
208	Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. **2012**, 104, 1094-101		157
207	Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy. *International Journal of Clinical Oncology*, **2012**, 17, 447-55	4.2	4
206	Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. **2012**, 14, 754-8		23
205	Comparative analysis of peptidylarginine deiminase-2 expression in canine, feline and human mammary tumours. **2012**, 147, 139-46		12
204	Patients younger than 40years old and older than 70years old affected by ER()/PR()/HER2() breast cancer have low survival rates: Results of a mono-institutional retrospective analysis. **2012**, 3, 312-319		
203	Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer. **2012**, 15, 197-202		18

202	Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. **2012**, 118, 2516-24	27
201	Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010. **2012**, 21, 366-73	36
200	Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. **2012**, 103, 1679-87	41
199	Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ?. **2012**, 36, 287-94	6
198	Association between breast cancer and allostatic load by race: National Health and Nutrition Examination Survey 1999-2008. **2013**, 22, 621-8	38
197	New biological insights on the link between radiation exposure and breast cancer risk. **2013**, 18, 3-13	13
196	Interleukin-8 in breast cancer progression. **2013**, 33, 563-70	104
195	Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012. **2013**, 34, 2349-55	12
194	Impact of body mass index on prognostically relevant breast cancer tumor characteristics. **2013**, 8, 192-8	19
193	Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000-2010. **2013**, 13, 449	66
192	Androgen receptor in triple negative breast cancer. **2013**, 133, 66-76	87
191	Hypothesized role of pregnancy hormones on HER2+ breast tumor development. *Breast Cancer Research and Treatment*, **2013**, 137, 237-46	4.4	17
190	Differences in breast cancer hormone receptor status in ethnic groups: a London population. **2013**, 49, 696-702	31
189	Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. **2013**, 104, 639-46	55
188	Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. **2013**, 20, 691-704	23
187	Screening mammography for women in their 40s: a retrospective study of the potential impact of the U.S. Preventive Service Task Force 2009 breast cancer screening recommendations. **2013**, 201, 1401-6	14
186	Population and target considerations for triple-negative breast cancer clinical trials. **2013**, 7, 11-21	9
185	Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. **2013**, 24, 2715-24	84

166	US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. **2014**, 106,		678
165	Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare data. **2014**, 14, 298		3
164	Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. *Breast Cancer Research and Treatment*, **2014**, 146, 439-46	4.4	26
163	Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. *Breast Cancer Research and Treatment*, **2014**, 146, 321-8	4.4	40
162	Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011). *Breast Cancer Research and Treatment*, **2014**, 145, 753-63	4.4	68
161	Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya. **2014**, 23, 591-6		40
160	Interactions of hormone replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk. **2014**, 20, 1169-78		14
159	Breast cancer characteristics and survival in a Hispanic population of costa rica. **2014**, 8, 103-8		8
158	Socioeconomic status and incidence of breast cancer by hormone receptor subtype. **2015**, 4, 508		54
157	A technique for relative quantitation of cancer biomarkers in formalin-fixed, paraffin-embedded (FFPE) tissue using stable-isotope-label based mass spectrometry imaging (SILMSI). **2015**, 50, 1088-1095		7
156	The Influence of Socioeconomic Status on Racial/Ethnic Disparities among the ER/PR/HER2 Breast Cancer Subtypes. **2015**, 2015, 813456		22
155	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. *Journal of Clinical Oncology*, **2015**, 33, 2254-61	2.2	170
154	The Potential Impact of Risk-Based Screening Mammography in Women 40-49 Years Old. **2015**, 205, 1360-4		18
153	The relationship between semaphorin 3C and microvessel density in the progression of breast and oral neoplasia. **2015**, 99, 19-24		16
152	St. Gallen endocrine response classes predict recurrence rates over time. **2015**, 24, 705-12		5
151	Breast Cancer Patients Undergoing Sentinel Node Biopsy: Additional Axillary Tumor Burden as a Function of the Total Number of Excised Sentinel Nodes-A Multicenter Study. **2015**, 15, 490-7		7
150	Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature. *Breast Cancer Research and Treatment*, **2015**, 153, 617-24	4.4	32
149	Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer. **2015**, 211, 421-5		26

148	Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification. **2015**, 17, 238-46		15
147	Breast Cancer Mortality among Asian-American Women in California: Variation according to Ethnicity and Tumor Subtype. **2016**, 19, 112-21		8
146	Aptamer-Assisted Detection of the Altered Expression of Estrogen Receptor Alpha in Human Breast Cancer. **2016**, 11, e0153001		19
145	Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis. **2016**, 13, e1002067		11
144	Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study. **2016**, 23, 291-302		18
143	Cancer Care Coordinators to Improve Tamoxifen Persistence in Breast Cancer: How Heterogeneity in Baseline Prognosis Impacts on Cost-Effectiveness. **2016**, 19, 936-944		
142	Retrospective analysis of breast cancer prognosis among young and older women in a Brazilian cohort of 738 patients, 1985-2002. **2016**, 12, 4911-4924		8
141	Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach. **2016**, 35, 152-8		4
140	Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer. *Breast Cancer Research and Treatment*, **2016**, 157, 145-56	4.4	12
139	Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities. **2016**, 35, 1367-73		48
138	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). *Breast Cancer Research and Treatment*, **2016**, 159, 109-18	4.4	26
137	Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. *Breast Cancer Research and Treatment*, **2016**, 157, 545-54	4.4	40
136	Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands. **2016**, 16, 712		2
135	Genomic Disparities in Breast Cancer Among Latinas. **2016**, 23, 359-372		32
134	Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. *Breast Cancer Research and Treatment*, **2016**, 158, 179-187	4.4	29
133	Glycolytic activity in breast cancer using 18 F-FDG PET/CT as prognostic predictor: A molecular phenotype approach. **2016**, 35, 152-158		
132	Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice. **2016**, 5, 395		7
131	Alcohol and breast cancer tumor subtypes in a Spanish Cohort. **2016**, 5, 39		12

130	Delayed Initiation of Adjuvant Chemotherapy Among Patients With Breast Cancer. **2016**, 2, 322-9		177
129	Integration of molecular pathology, epidemiology and social science for global precision medicine. **2016**, 16, 11-23		69
128	Breast Cancer Subtype Variation by Race and Ethnicity in a Diverse Population in British Columbia. **2016**, 16, e49-55		8
127	The effects of bufadienolides on HER2 overexpressing breast cancer cells. **2016**, 37, 7155-63		6
126	Genetic testing in a cohort of young patients with HER2-amplified breast cancer. **2016**, 27, 467-73		16
125	BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis. **2017**, 27, 143-151		37
124	Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities. *Breast Cancer Research and Treatment*, **2017**, 163, 151-158	4.4	13
123	Lifetime moderate-to-vigorous physical activity and ER/PR/HER-defined post-menopausal breast cancer risk. *Breast Cancer Research and Treatment*, **2017**, 165, 201-213	4.4	5
122	The Interaction between Genetic Ancestry and Breast Cancer Risk Factors among Hispanic Women: The Breast Cancer Health Disparities Study. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 692-701	4	14
121	Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks. **2017**, 148, 199-207		8
120	Breast Cancer Disparities: Socioeconomic Factors versus Biology. **2017**, 24, 2869-2875		52
119	Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival. *Breast Cancer Research and Treatment*, **2017**, 165, 163-168	4.4	8
118	Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors. *Breast Cancer Research and Treatment*, **2017**, 165, 743-750	4.4	32
117	Clinical and pathological features of breast cancer in a population of Mexico. **2017**, 85, 201-207		1
116	Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. **2017**, 22, 1292-1300		56
115	[Clinical and pathological features of breast cancer in a population of Mexico]. **2017**, 85, 201-207		5
114	Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions. **2017**, 151, 33-80		4
113	Dipalmitoylphosphatidic acid inhibits tumor growth in triple-negative breast cancer. **2017**, 13, 471-479		6

94	Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. **2018**, 285, 23-34		37
93	Quantifying heterogeneity of expression data based on principal components. **2019**, 35, 553-559		1
92	Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody. **2019**, 8, 676-684		6
91	HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women. **2019**, 19, 1		11
90	Epidemiological characteristics of and risk factors for breast cancer in the world. **2019**, 11, 151-164		185
89	Patterns of endocrine therapy in a national cohort of early stage HER2-positive breast cancer patients. **2019**, 28, 812-820		6
88	Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2- breast cancer subtypes. **2019**, 30, 417-424		2
87	Semaphorin 3C as a Therapeutic Target in Prostate and Other Cancers. **2019**, 20,		11
86	Differentially expressed microRNAs in exosomes of patients with breast cancer revealed by next-generation sequencing. **2020**, 43, 240-250		22
85	Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. **2019**, 19, 874		7
84	Grade-lymph node ratio predicts the survival of breast cancer in different molecular types: A surveillance, epidemiology, and end results population-based analysis. *Medicine (United States)*, **2019**, 98, e16436	1.8	3
83	Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women. **2019**, 22, 185-193		9
82	Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. **2019**, 145, 821-828		4
81	Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program. *Breast Cancer Research and Treatment*, **2019**, 173, 693-699	4.4	3
80	Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer. *Breast Cancer Research and Treatment*, **2019**, 174, 615-625	4.4	34
79	Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran. **2019**, 14, e0208701		6
78	Molecular Mechanisms of Endocrine Resistance. **2019**, 265-307		4
77	The high and heterogeneous burden of breast cancer in Hawaii: A unique multiethnic U.S. Population. **2019**, 58, 71-76		2

76	It is time to apply biclustering: a comprehensive review of biclustering applications in biological and biomedical data. **2019**, 20, 1449-1464	22
75	Correlation of the protein expression of GRP78 and BIK/NBK with prognostic markers in patients with breast cancer and neoadjuvant chemotherapy. **2020**, 40, 419-426	3
74	Long-term prognostic effect of hormone receptor subtype on breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 139-151	4.4 2
73	EEF1A2 triggers stronger ERK mediated metastatic program in ER negative breast cancer cells than in ER positive cells. **2020**, 262, 118553	1
72	Cancer progression and the invisible phase of metastatic colonization. **2020**, 20, 681-694	60
71	Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. **2020**, 12,	7
70	Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis. **2021**, 21, e497-e505	3
69	Prevalence of Histological Characteristics of Breast Cancer in Rwanda in Relation to Age and Tumor Stages. **2020**, 11, 240-249	3
68	UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells. **2020**, 492, 21-30	2
67	Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan. **2021**, 21, 903-913	11
66	Factors associated with being diagnosed with high severity of breast cancer: a population-based study in Queensland, Australia. *Breast Cancer Research and Treatment*, **2020**, 184, 937-950	4.4 0
65	Genomic Strategies for Personalized Cancer Therapy. **2020**, 1-60	
64	Breast cancer in togolese women: immunohistochemistry subtypes. **2020**, 20, 261	1
63	Breast cancer in elderly Korean women: clinicopathological and biological features. **2020**, 39, 71-83	1
62	Neoadjuvant chemotherapy modifies serum pyrrolidone carboxypeptidase specific activity in women with breast cancer and influences circulating levels of GnRH and gonadotropins. *Breast Cancer Research and Treatment*, **2020**, 182, 751-760	4.4 4
61	Pen: A novel plasma source for cancer treatment. **2020**, 11, 2273-2282	17
60	Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes. **2020**, 128, 298-307	3
59	Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. **2020**, 80, 1893-1901	10

58	Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072. **2021**, 109, 383-393	6
57	BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. **2021**, 1875, 188459	2
56	Cancer health disparities in racial/ethnic minorities in the United States. **2021**, 124, 315-332	110
55	Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer. **2021**, 28, 100401	1
54	Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings. **2021**, 15, 11782234211020242	0
53	Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. **2021**, 21, 149	11
52	Differences in Breast Cancer Presentation at Time of Diagnosis for Black and White Women in High Resource Settings. **2021**, 23, 1305-1342	1
51	miRNAs Modulate the Dichotomy of Cisplatin Resistance or Sensitivity in Breast Cancer: An Update of Therapeutic Implications. **2021**, 21, 1069-1081	3
50	Discordance Between Immunohistochemistry and In Situ Hybridization to Detect HER2 Overexpression/Gene Amplification in Breast Cancer in the Modern Age: A Single Institution Experience and Pooled Literature Review Study. **2021**,	1
49	Individual- and neighborhood-level socioeconomic status and risk of aggressive breast cancer subtypes in a pooled cohort of women from Kaiser Permanente Northern California. **2021**, 127, 4602-4612	1
48	Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. **2021**, 13,	49
47	Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience. **2021**, 13,	1
46	In Vitro Targeting of NL2 Peptide Bounded on Poly L-DOPA Coated Graphene Quantum Dot. **2021**, 31, 279-288	4
45	Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. **2021**, 15, 1178223421995854	4
44	Breast Cancer Risk and Mortality in Women of Latin American Origin. **2020**, 45-55	2
43	Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences. **2021**, 81, 317-331	35
42	Breast cancer - one term, many entities?. **2011**, 121, 3789-96	152
41	Epidemiological And Biological Profiling Of Breast Cancer In Southern Morocco. 5,	1

40	The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case. **2016**, 3, 268-274		3
39	Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients. **2018**, 9, 23173-23182		2
38	Overexpression of UHRF1 and its potential role in the development of invasive ductal breast cancer validated by integrative bioinformatics and immunohistochemistry analyses.. **2019**, 8, 1086-1096		0
37	Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy?. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2019**, 31, 878-891	3.8	2
36	Naphthol-derived Betti bases as potential SLC6A14 blockers. *Journal of Molecular and Clinical Medicine*, **2019**, 2, 35	0.4	3
35	Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors. *Frontiers in Public Health*, **2020**, 8, 576964	6	17
34	Black-White Disparities in Breast Cancer Subtype: The Intersection of Socially Patterned Stress and Genetic Expression. *AIMS Public Health*, **2017**, 4, 526-556	1.9	24
33	Clinicopathological profile of breast cancer: An institutional experience. *Indian Journal of Cancer*, **2018**, 55, 210-213	0.9	9
32	Diagnostic and prognostic importance of the neutrophil lymphocyte ratio in breast cancer. *Asian Pacific Journal of Cancer Prevention*, **2014**, 15, 10363-6	1.7	13
31	Survival time and molecular subtypes of breast cancer after radiotherapy in Thailand. *Asian Pacific Journal of Cancer Prevention*, **2014**, 15, 10505-8	1.7	9
30	Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients. *Asian Pacific Journal of Cancer Prevention*, **2016**, 17, 1973-8	1.7	12
29	Breast Cancer Incidence and Mortality by Molecular Subtype: Statewide Age and Racial/Ethnic Disparities in New Jersey. *Cancer Health Disparities*, **2019**, 3, e1-e17	1.1	12
28	Expression of ER, PR, HER-2, PCNA and P53 genes in breast cancer patients in Shanghai and the relevant clinical significance. *Academic Journal of Second Military Medical University*, **2010**, 30, 748-752		
27	A need for screening and early diagnosis of breast cancer. *Asian Biomedicine*, **2019**, 13, 1-2	0.4	
26	Breast Cancer Screening. **2020**, 297-312		0
25	Optimization of HER2-based and cell-based ELISA for detection of trastuzumab biosimilar. *Koomesh*, **2020**, 22, 341-350	0.3	0
24	UDP-Glucose 6-Dehydrogenase Knockout Impairs Migration and Decreasesin vivoMetastatic Ability of Breast Cancer Cells.		
23	Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 351-363	4	2

22	Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico. *Puerto Rico Health Sciences Journal*, **2010**, 29, 265-71	0.5	2
21	Distinct breast cancer subtypes in women with early-onset disease across races. *American Journal of Cancer Research*, **2014**, 4, 337-52	4.4	15
20	A retrospective study of the clinical differences of Uygur breast cancer patients compared to Han breast cancer patients in the Xinjiang region of China. *International Journal of Clinical and Experimental Medicine*, **2014**, 7, 3482-90		6
19	Triple Negative Breast Cancer at the University Hospital Mohammed VI Dujda. *Asian Pacific Journal of Cancer Prevention*, **2017**, 18, 195-200	1.7	2
18	The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.. *International Journal of Clinical Oncology*, **2022**, 27, 707	4.2	
17	Ultrasonographic morphological characteristics determined using a deep learning-based computer-aided diagnostic system of breast cancer.. *Medicine (United States)*, **2022**, 101, e28621	1.8	0
16	Breast cancer management in 2021: A primer for the obstetrics and gynecology.. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2022**,	4.6	1
15	Untargeted Metabolomics of Breast Cancer Cells MCF-7 and SkBr3 Treated With Tamoxifen/Trastuzumab.. *Cancer Genomics and Proteomics*, **2022**, 19, 79-93	3.3	1
14	Orobanche crenata Forssk. Extract Affects Human Breast Cancer Cell MCF-7 Survival and Viral Replication. *Cells*, **2022**, 11, 1696	7.9	1
13	Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype. *Breast Cancer Research and Treatment*,	4.4	0
12	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer. *Journal of Clinical Oncology*,	2.2	1
11	Integrative, In Silico and Comparative Analysis of Breast Cancer Secretome Highlights Invasive-Ductal-Carcinoma-Grade Progression Biomarkers. **2022**, 14, 3854		
10	Pyridine ring as an important scaffold in anticancer drugs. **2023**, 375-410		0
9	Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review. **2022**, 2022, 1-7		0
8	Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer. **2022**, 2022,		0
7	Genetic Ancestry and Breast Cancer Subtypes in Hispanic/Latina Women. **2023**, 79-88		0
6	Integrative prognostic analysis of tumor infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.		0
5	Liver metastasis in estrogen receptor-positive HER 2-negative breast cancer. Ribociclib as prognosis-changing therapy. **2022**, 13-19		0

4	Characteristics and chronologically changing patterns of late-onset breast cancer in Korean women of age 70 years: A hospital based-registry study. **2022**, 22,	0
3	Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer.	0
2	Hormone Receptors and HER-2 Status as Surrogates for Breast Cancer Molecular Subtypes Prognosticate for Disease Control in Node Negative Asian Patients Treated with Breast Conservation Therapy. **2011**, 40, 90-96	0
1	Locally Advanced Breast Cancer: Response Evaluation to Neoadjuvant Chemotherapy by Clinico-Histopathological Parameters and Molecular Imaging.	0